EU approves Amgen's bone drug Xgeva for cancer patients

07/18/2011 | InPharm.com

European regulators approved Amgen's Xgeva, or denosumab, for preventing fractures and other skeletal events in adults with solid tumors. The approval provides Amgen another year of market exclusivity. Denosumab also is marketed as Prolia for osteoporosis.

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA